Direct-acting antiviral treatment failure in genotype 2 hepatitis C chronic infection.
作者信息
Ridruejo Ezequiel, Piñero Federico, Mendizabal Manuel, Silva Marcelo
机构信息
Hepatology Section, Department of Medicine, Centro de Educación Médica e Investigaciones Clínicas, CEMIC, Ciudad Autónoma de Buenos Aires, Argentina.
Hepatology and Liver Transplant Unit, Hospital Universitario Austral, Pilar, Argentina.
出版信息
J Viral Hepat. 2021 Feb;28(2):446-447. doi: 10.1111/jvh.13433. Epub 2020 Nov 18.
PMID:33147362
Abstract
摘要
相似文献
1
Direct-acting antiviral treatment failure in genotype 2 hepatitis C chronic infection.2型丙型肝炎慢性感染中直接抗病毒治疗失败
J Viral Hepat. 2021 Feb;28(2):446-447. doi: 10.1111/jvh.13433. Epub 2020 Nov 18.
2
Sofosbuvir Causing Diabetes Mellitus: Is there a Link?索非布韦会引发糖尿病吗？两者有关联吗？
J Coll Physicians Surg Pak. 2018 May;28(5):414. doi: 10.29271/jcpsp.2018.05.414.
3
Sofosbuvir-/Daclatasvir-based therapy for chronic HCV and HCV/hepatitis B virus coinfected patients in Egypt.索磷布韦/达卡他韦方案治疗埃及慢性丙型肝炎及丙型肝炎/乙型肝炎病毒合并感染患者。
Trans R Soc Trop Med Hyg. 2020 Feb 7;114(3):200-212. doi: 10.1093/trstmh/trz079.
4
Decentralised hepatitis C testing and treatment in rural Cambodia: evaluation of a simplified service model integrated in an existing public health system.柬埔寨农村地区丙型肝炎的分散检测和治疗：评估整合到现有公共卫生系统中的简化服务模式。
Lancet Gastroenterol Hepatol. 2021 May;6(5):371-380. doi: 10.1016/S2468-1253(21)00012-1. Epub 2021 Mar 19.
5
Virological patterns of hepatitis C virus patients with failure to the current-generation direct-acting antivirals.慢性丙型肝炎病毒患者对当前代直接作用抗病毒药物治疗失败的病毒学模式。
Int J Antimicrob Agents. 2020 Sep;56(3):106067. doi: 10.1016/j.ijantimicag.2020.106067. Epub 2020 Jun 26.
6
2017 KASL clinical practice guidelines management of hepatitis C: Treatment of chronic hepatitis C.2017年丙型肝炎管理的KASL临床实践指南：慢性丙型肝炎的治疗
Clin Mol Hepatol. 2018 Sep;24(3):169-229. doi: 10.3350/cmh.2018.1004. Epub 2018 Aug 10.
7
What is the Long-term Benefit of Direct-acting Antiviral Therapy in Chronic Hepatitis C?直接抗病毒疗法治疗慢性丙型肝炎的长期益处是什么？
J Korean Med Sci. 2019 Oct 28;34(41):e277. doi: 10.3346/jkms.2019.34.e277.
8
Safety and efficacy of sofosbuvir-based direct-acting antiviral regimens for hepatitis C virus genotype 6 in Southwest China: Real-world experience of a retrospective study.中国西南地区基于索磷布韦的直接作用抗病毒方案治疗丙型肝炎病毒基因型 6 的安全性和疗效：一项回顾性研究的真实世界经验。
J Viral Hepat. 2019 Mar;26(3):316-322. doi: 10.1111/jvh.13033. Epub 2018 Dec 3.
9
Treatment of hepatitis C virus infection with direct-acting antivirals plus ribavirin eliminates viral RNA from peripheral blood mononuclear cells and reduces virologic relapse in diverse hepatic parenchymal changes.直接作用抗病毒药物联合利巴韦林治疗丙型肝炎病毒感染可从外周血单核细胞中消除病毒 RNA，并减少各种肝实质变化中的病毒学复发。
Arch Virol. 2021 Apr;166(4):1071-1081. doi: 10.1007/s00705-021-04969-4. Epub 2021 Feb 3.
10
Ribavirin induces hepatitis C virus genome mutations in chronic hepatitis patients who failed to respond to prior daclatasvir plus asunaprevir therapy.利巴韦林诱导先前达拉他韦联合阿舒瑞韦治疗无应答的慢性丙型肝炎患者的丙型肝炎病毒基因组突变。
J Med Virol. 2020 Feb;92(2):210-218. doi: 10.1002/jmv.25602. Epub 2019 Oct 16.
Zotero 插件